Physician profile
Brian Spence
NPI 1083268718
$1,613.23
in general payments reported to CMS, 2019-2025
13 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $702 · 2023: $138 · 2024: $362 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.72 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $631.97 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $228.70 | 2022-2024 | Spravato, Invega Sustenna |
| Lundbeck LLC | $107.96 | 2022-2025 | Abilify Maintena |
| Merck Sharp & Dohme LLC | $99.75 | 2023-2024 | Pifeltro, Delstrigo, Dificid |
| Alkermes, INC. | $91.57 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $84.33 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.27 | 2021-2022 | |
| Viiv Healthcare Company | $72.98 | 2024 | Rukobia, Apretude |
| Otsuka America Pharmaceutical, INC. | $65.59 | 2022 | |
| Neurocrine Biosciences, INC. | $57.71 | 2025 | |
| Gilead Sciences, INC. | $47.68 | 2023-2024 | |
| Hologic Sales and Service, LLC | $24.51 | 2024 | Aptima, Thinprep 2000 Processor |
| Indivior INC. | $17.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Spence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.